PRNewsWire
14 Aug 2026, 19:38 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA stated that the HOPE-3 study for Deramiocel did not meet its pre-specified primary and secondary efficacy endpoints. — Failure to meet primary endpoints in a pivotal Phase 3 trial severely jeopardizes the drug's approval and the company's primary value driver.
-0.90The FDA revealed that Capricor modified its statistical analysis plan (SAP) without FDA agreement prior to resubmitting its Biologics License Application. — Unauthorized changes to data analysis plans suggest potential data manipulation or 'p-hacking,' which destroys regulatory trust and credibility.
-0.70A securities fraud class action lawsuit has been filed against Capricor alleging materially false and misleading statements regarding clinical trial data. — Litigation introduces additional financial liability and management distraction, though it follows the primary negative catalyst of the FDA report.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a securities fraud class action lawsuit following allegations of misleading clinical trial data and a 64% stock price collapse.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
59m ago
